Literature DB >> 17092820

P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: epidemiology and role in clinical resistance to antifolates.

C V Plowe1, J G Kublin, O K Doumbo.   

Abstract

Plasmodium falciparum resistance to the antifolates has arisen rapidly in Asia and South America, and threatens the usefulness of these drugs in Africa. In vitro resistance to the antifolates is determined by mutations in parasite dihydrofolate reductase (DHFR) and dihydropteroate synthase (DHPS). The role of DHFR and DHPS mutations in therapeutic failure of antifolate antimalarials is less clear. This review summarizes molecular epidemiological surveys, studies of in vivo selection of mutant alleles by drug treatment, and prospective studies of the ability of mutation-specific assays to predict clinical outcomes, and discusses the potential use of these assays for surveillance of resistance.

Entities:  

Year:  1998        PMID: 17092820     DOI: 10.1016/s1368-7646(98)80014-9

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  45 in total

1.  Plasmodium falciparum Drug-Resistant Haplotypes and Population Structure in Postearthquake Haiti, 2010.

Authors:  Lindsay Carol Morton; Curtis Huber; Sheila Akinyi Okoth; Sean Griffing; Naomi Lucchi; Dragan Ljolje; Jacques Boncy; Roland Oscar; David Townes; Meredith McMorrow; Michelle A Chang; Venkatachalam Udhayakumar; John W Barnwell
Journal:  Am J Trop Med Hyg       Date:  2016-07-18       Impact factor: 2.345

2.  Plasmodium falciparum strains harboring dihydrofolate reductase with the I164L mutation are absent in Malawi and Zambia even under antifolate drug pressure.

Authors:  Edwin Ochong; David J Bell; David J Johnson; Umberto D'Alessandro; Modest Mulenga; Sant Muangnoicharoen; Jean-Pierre Van Geertruyden; Peter A Winstanley; Patrick G Bray; Stephen A Ward; Andrew Owen
Journal:  Antimicrob Agents Chemother       Date:  2008-08-25       Impact factor: 5.191

3.  Benefits of using multiple first-line therapies against malaria.

Authors:  Maciej F Boni; David L Smith; Ramanan Laxminarayan
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

Review 4.  Drug-resistant malaria in Sudan: A review of evidence and scenarios for the future.

Authors:  Ahmed Awad Adeel
Journal:  Sudan J Paediatr       Date:  2012

Review 5.  Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present.

Authors:  Carol Hopkins Sibley; Ric N Price
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2012-04-20       Impact factor: 4.077

6.  Increasing prevalence of a novel triple-mutant dihydropteroate synthase genotype in Plasmodium falciparum in western Kenya.

Authors:  Naomi W Lucchi; Sheila Akinyi Okoth; Franklin Komino; Philip Onyona; Ira F Goldman; Dragan Ljolje; Ya Ping Shi; John W Barnwell; Venkatachalam Udhayakumar; Simon Kariuki
Journal:  Antimicrob Agents Chemother       Date:  2015-04-20       Impact factor: 5.191

7.  Sulfadoxine-pyrimethamine resistance in the rodent malaria parasite Plasmodium chabaudi.

Authors:  Karen Hayton; Lisa C Ranford-Cartwright; David Walliker
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Common origin and fixation of Plasmodium falciparum dhfr and dhps mutations associated with sulfadoxine-pyrimethamine resistance in a low-transmission area in South America.

Authors:  Andrea M McCollum; Kristen Mueller; Leopoldo Villegas; Venkatachalam Udhayakumar; Ananias A Escalante
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

9.  Hitchhiking and selective sweeps of Plasmodium falciparum sulfadoxine and pyrimethamine resistance alleles in a population from central Africa.

Authors:  Andrea M McCollum; Leonardo K Basco; Rachida Tahar; Venkatachalam Udhayakumar; Ananias A Escalante
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

10.  The evolution of drug-resistant malaria.

Authors:  Christopher V Plowe
Journal:  Trans R Soc Trop Med Hyg       Date:  2008-12-12       Impact factor: 2.184

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.